Prevalence of High Tumor Mutational Burden and Association With Survival in Patients With Less Common Solid Tumors.

ABSTRACT:

Importance

Tumor mutational burden (TMB) is a potential biomarker associated with response to immune checkpoint inhibitor therapies. The prognostic value associated with TMB in the absence of immunotherapy is uncertain.

Objective

To assess the prevalence of high TMB (TMB-H) and its association with overall survival (OS) among patients not treated with immunotherapy with the same 10 tumor types from the KEYNOTE-158 study.

Design, setting, and participants

This retrospective cohort study evaluated the prognostic value of TMB-H, assessed by Foundation Medicine (FMI) and defined as at least 10 mutations/megabase (mut/Mb) in the absence of immunotherapy. Data were sourced from the deidentified Flatiron Health-FMI clinicogenomic database collected up to July 31, 2018. Eligi

SUBMITTER: Shao C 

PROVIDER: S-EPMC7596577 | biostudies-literature | 2020 Oct

REPOSITORIES: biostudies-literature